Blue Earth Diagnostics
http://www.blueearthdiagnostics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Blue Earth Diagnostics
FDA’s New PSG Batch Features GSK’s Inhalers
In its latest batch of product-specific guidances, the FDA released multiple new and revised guidances on inhalers, including several on GSK’s products such as Relenza and the Ellipta trio.
Deals in Depth August 2023
In the top August alliance by deal value, Precision BioSciences licensed Imugene global rights to azercabtagene zapreleucel (azer-cel), its lead allogeneic anti-CD19 CAR T candidate for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future. Precision will receive $21m up front and is eligible for $8m upon successful completion of the Phase Ib dosing in the CAR T relapsed LBCL patient population. For azer-cel, Precision is eligible to receive up to $198m in additional milestone payments plus royalties. For each additional research program selected by Imugene, Precision is eligible for up to $145m in milestone payments and tiered royalties on net sales.
News We’re Watching: Two Join Illumina Board, FDA Plans Health Equity Meeting, Pre-Eclampsia Test Cleared
This week, Illumina’s board added two independent members; the VA and the FDA agreed to collaborate on supply chain issues; and Think Surgical, Thermo Fisher Scientific and Blue Earth all landed FDA clearances.
Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
-
- Blue Earth Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice